Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234967 | 0.93 | BCHE (0.47) | OPRM1OPRK1ACHEBCHEKDM4E | |
| SCHEMBL2238595 | 0.88 | ALDH1A1 (0.47) | OPRM1ACHEBCHEKDM4EHRH3 | |
| SCHEMBL2237426 | 0.88 | HTR2C (0.43) | ACHEBCHEKDM4ELTA4HHTR2C | |
| SCHEMBL2237555 | 0.88 | BCHE (0.54) | ACHEBCHEKDM4ELTA4HHTR2C | |
| SCHEMBL2235515 | 0.85 | KDM4E (0.50) | OPRM1OPRK1ACHEBCHEKDM4E | |
| SCHEMBL2236466 | 0.84 | BCHE (0.44) | ACHEBCHEKDM4ELTA4HHTR2C | |
| SCHEMBL2239984 | 0.83 | HDAC1 (0.44) | OPRM1ACHEBCHELTA4HHTR2C | |
| SCHEMBL2237880 | 0.82 | HTR2C (0.43) | ACHEBCHEHTR2CSLC6A4PKM | |
| SCHEMBL1936097 | 0.81 | HTT (0.51) | BCHEKDM4ELTA4HALDH1A1PKM | |
| SCHEMBL1935383 | 0.81 | HTR2C (0.43) | ACHEBCHEHTR2CSLC6A4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | OPRM1 503/4885OPRK1 198/4885ACHE 1217/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | OPRM1 442/4885OPRK1 162/4885ACHE 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.